Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$2.17 USD
-0.06 (-2.69%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $2.18 +0.01 (0.46%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRVS 2.17 -0.06(-2.69%)
Will CRVS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRVS
Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
CRVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
What Makes Corvus (CRVS) a New Buy Stock
Other News for CRVS
Corvus Pharmaceuticals Is Ready To Take Flight
The 2024 Millionaire’s Club: 3 Penny Stocks to Buy Now
Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference
Fly Insider: Sensata, BioMarin among week's notable insider trades
Biotech Alert: Searches spiking for these stocks today